XNAS · Healthcare · Biotechnology
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Biotech platform company **beat EPS expectations** despite revenue miss, maintaining $4.3B cash position while executing $109.7M share repurchase program this quarter.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q4 2026 | -0.36 | -0.27 | +23.89% | $2.5M | ✅ Beat | -0.11% | -8.73% | — |
| 2026-02-06 | Q3 2026 | -0.34 | -0.24 | +29.41% | $2.0M | ✅ Beat | -0.90% | +2.44% | +14.37% |
| 2025-11-10 |
| Q2 2026 |
| -0.32 |
| -0.28 |
| +12.50% |
| $1.6M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q1 2026 | -0.26 | -0.25 | +3.85% | $2.2M | ✅ Beat | -4.18% | +5.73% | +23.28% |
| 2025-02-10 | Q3 2025 | -0.24 | -0.20 | +16.67% | $9.0M | ✅ Beat | -2.78% | -1.02% | -1.76% |
| 2024-05-30 | Q4 2024 | -0.30 | -0.19 | +36.67% | $28.9M | ✅ Beat | -0.29% | +2.21% | +4.23% |
| 2024-02-13 | Q3 2024 | -0.32 | -0.21 | +34.38% | $37.1M | ✅ Beat | — | — | — |
| 2023-11-13 | Q2 2024 | -0.31 | -0.40 | -29.03% | $37.1M | ❌ Miss | +2.76% | -2.76% | +19.45% |
Showing last 8 quarters.